Evidence map›Paper›PMID 38534933›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.

Lilit Harutyunyan, Evelina Manvelyan, Nune Karapetyan, Samvel Bardakhchyan, Aram Jilavyan, Gevorg Tamamyan, Armen Avagyan, Liana Safaryan, Davit Zohrabyan, Narine Movsisyan and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lilit HarutyunyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.ORCID 0009-0001-0174-6977
Evelina ManvelyanDepartment of Reproductive Biology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0000-0001-9796-6351
Nune KarapetyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.
Samvel BardakhchyanClinic of Adults' Oncology and Chemotherapy at Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
Aram JilavyanNational Center of Oncology of Armenia, 76 Fanarjyan St., Yerevan 0052, Armenia.
Gevorg TamamyanImmune Oncology Research Institute, 7 Nersisyan St., Yerevan 0014, Armenia.
Armen AvagyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.
Liana SafaryanClinic of Adults' Oncology and Chemotherapy at Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
Davit ZohrabyanClinic of Adults' Oncology and Chemotherapy at Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
Narine MovsisyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.
Anna AvinyanOncology Clinic, Mikaelyan Institute of Surgery, Ezras Hasratian 9, Yerevan 0052, Armenia.
Arevik GaloyanOncology Clinic, Mikaelyan Institute of Surgery, Ezras Hasratian 9, Yerevan 0052, Armenia.
Mariam SargsyanOncology Clinic, Mikaelyan Institute of Surgery, Ezras Hasratian 9, Yerevan 0052, Armenia.
Martin HarutyunyanClinic of Adults' Oncology and Chemotherapy at Yeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
Hasmik NersoyanNational Center of Oncology of Armenia, 76 Fanarjyan St., Yerevan 0052, Armenia.
Arevik StepanyanNational Center of Oncology of Armenia, 76 Fanarjyan St., Yerevan 0052, Armenia.
Armenuhi GalstyanNational Center of Oncology of Armenia, 76 Fanarjyan St., Yerevan 0052, Armenia.
Samvel DanielyanYeolyan Hematology and Oncology Center, 7 Nersisyan St., Yerevan 0014, Armenia.
Armen MuradyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.
Gagik JilavyanDepartment of General Oncology, Yerevan State Medical University after M. Heratsi, 2 Koryun St., Yerevan 0025, Armenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnnually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia based on the type of recurrence, risk factors, and choice of systemic treatment.

methodsThis retrospective case-control study included 228 patients with relapsed ovarian cancer from three different institutions.

resultsThe median age of the patients was 55. The median follow-up times from relapse and primary diagnosis were 21 and 48 months, respectively. The incidence of platinum-sensitive relapse was 81.6% (186), while platinum-resistant relapse was observed in only 18.4% (42) of patients. The median post-progression survival of the platinum-sensitive group compared to the platinum-resistant group was 54 vs. 25 months (

conclusionsOverall, despite new therapeutic approaches, ovarian cancer continues to be one of the deadly malignant diseases affecting women, especially in developing countries with a lack of resources, where chemotherapy remains the primary available systemic treatment for the majority of patients. Low survival rates demonstrate the urgent need for more research focused on this group of patients with poor outcomes.

Indexed as

Neoplasm Recurrence, LocalOvarian NeoplasmsArmeniaCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansRecurrenceRetrospective StudiesSurvival Analysischemotherapyplatinum-refractory relapseplatinum-resistant relapseplatinum-sensitive relapserecurrent ovarian cancertargeted therapy

Identifiers

PMID38534933
PMCPMC10968888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.